An observational study in Primary Hyperparathyroidism and Primary Hyperparathyroidism Due to Adenoma, sponsored by University Medical Center Groningen. Completed. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-04-16.
Sponsored by University Medical Center Groningen · Observational
The leading cause of primary hyperparathyroidism (pHPT) is a solitary adenoma (89%). The treatment of pHPT is generally surgical removal of the overactive parathyroid gland(s). Since a solitary adenoma is the predominant cause, parathyroid surgery is preferably performed through a minimally invasive parathyroidectomy (MIP) in which only the suspected adenoma causing the pHPT is resected in a focused manner. To facilitate the performance of a MIP, accurate preoperative imaging is pivotal. This study aimed to analyze the diagnostic performance of 11C-choline PET/CT after prior negative or discordant first-line imaging in patients with pHPT undergoing parathyroid surgery with an optimized imaging protocol.
105 studies on the registry are indexed under Hyperparathyroidism, Primary; 23 are open to participants now.
This study's enrollment of 36 is below the median of 145 across 42 observational studies indexed under Hyperparathyroidism, Primary.
Browse Hyperparathyroidism, Primary studies →University Medical Center Groningen is the lead sponsor of 625 studies on the registry; 174 are open to participants now.
Counted across the registry records on this site, refreshed daily.
This is a retrospective single-center cohort study of patients with biochemically proven pHPT who underwent parathyroid surgery after localization by means of 11C-choline PET/CT and negative or discordant first-line imaging in a teaching and tertiary referral hospital in the Netherlands between 2015 and 2019.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Patients eligible for inclusion were ≥18 years old, diagnosed with biochemically confirmed pHPT, underwent a MIBI-SPECT/CT and/or cUS with negative or discordant results, and underwent a 11C-choline PET/CT followed by parathyroidectomy.
Exclusion Criteria:
Patients were excluded if they were known to have a germline mutation predisposing for familial hypocalciuric hypercalcemia (FHH).
Patients with biochemically proven primary hyperparathyroidism who underwent parathyroid surgery after localization by means of 11C-choline PET/CT and negative or discordant first-line imaging
Diagnostic Test: 11C-choline PET/CT
11C-choline PET/CT
Sensitivity of 11C-choline PET/CT
Per-lesion sensitivity of 11C-choline PET/CT for the detection of overactive parathyroid glands
Time frame: Until 6 months after parathyroid surgery
Positive predictive value of 11C-choline PET/CT
Per-lesion positive predictive value of 11C-choline PET/CT for the detection of overactive parathyroid glands
Time frame: Until 6 months after parathyroid surgery
Accuracy of 11C-choline PET/CT
Per-lesion accuracy of 11C-choline PET/CT for the detection of overactive parathyroid glands
Time frame: Until 6 months after parathyroid surgery
No study locations are listed for this record.
Plan to share: Undecided — Available upon reasonable request via the principle investigator
No publications or documents are linked to this record.
Ran from Jan 2015 to primary completion in Dec 2019, 59 months.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Hyperparathyroidism, Primary →
University Medical Center Groningen →